155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study
Title:
155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study
Author:
Lu, M. Yu, X. Chen, Z. Zhang, Y. Li, Z. Zhang, X. Yin, F. Ye, F. Cheng, Y. Song, L. Xu, J. Zhou, J. Shi, H. Tan, P. Fan, S. Su, W. Shen, L.